Vaccine maker Moderna's chief executive officer Stephane Bancel will vacate his role as the company's chief commercial ...

Stephane Bancel is stepping down as chief commercial officer of Moderna Inc., according to a person familiar with the matter.

Heading into Moderna’s third-quarter earnings, investors and analysts will be watching to see how the Cambridge drugmaker ...

Moderna MRNA is set to report third-quarter 2024 earnings on Nov. 7, before the opening bell. The Zacks Consensus Estimate ...

JPMorgan analyst Jessica Fye lowered the firm’s price target on Moderna (MRNA) to $59 from $70 and keeps an Underweight rating on the shares. The firm updated estimates following Pfizer’s Comirnaty ...

Moderna, a biotech giant that gained prominence during the COVID-19 pandemic, has revolutionized the biotechnology domain.

In August, the Food and Drug Administration authorized updated vaccines against COVID-19. Here's what to know about the three ...

Current Moderna shareholders who have held Moderna shares since on or before January 18, 2023, can seek corporate reforms, the return of funds spent defending litigation back to the company, and a ...

Shares of Moderna Inc. MRNA inched 0.55% higher to $53.09 Friday, on what proved to be an all-around mixed trading session ...

For a drugmaker advancing medicines through clinical trials, time is the enemy: the longer the process takes, the more costs ...

We recently published a list of 10 Best Depressed Stocks To Buy Heading into 2025. In this article, we are going to take a ...

A WhatsApp message has earned Moderna a reprimand from the UK's Prescription Medicines Code of Practice Authority (PMCPA), ...